Yazar "Horakova, Dana" için listeleme
-
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Brown, J. William L.; Coles, Alasdair; Horakova, Dana; Havrdova, Eva; Izquierdo, Guillermo; Prat, Alexandre; Pucci, Eugenio (Amer Medical Assoc, 2019)IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between ... -
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Kalincik, Tomas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Havrdova, Eva; Trojano, Maria; Barnett, Michael (Sage Publications Ltd, 2018)Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon , fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, ... -
A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
Spelman, Timothy; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Butzkueven, Helmut (Lippincott Williams & Wilkins, 2018)… -
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Turkoglu, Recai (Bmj Publishing Group, 2019)Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed. Methods We identified all patients with ... -
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
He, Anna; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Luis Sanchez-Menoyo, Jose (Amer Medical Assoc, 2015)IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is ... -
Defining reliable disability outcomes in multiple sclerosis
Kalincik, Tomas; Cutter, Gary; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Ramo, Cristina (Oxford Univ Press, 2015)Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. The disability outcomes used in most clinical trials rely on progression of Expanded Disability ... -
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis
Tao, Chunrong; Simpson, Steve; van der Mei, Ingrid; Blizzard, Leigh; Havrdova, Eva; Horakova, Dana; Barnett, Michael (Bmj Publishing Group, 2016)Background Age at onset (AAO) in multiple sclerosis (MS) is an important marker of disease severity and may have prognostic significance. Understanding what factors can influence AAO may shed light on the aetiology of this ... -
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Nguyen, Ai-Lan; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Kalincik, Tomas; van der Walt, Anneke; Granella, Franco (Elsevier Sci Ltd, 2019)Background: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RAMS) may be increasing. Objective: To retrospectively determine incidence of pregnancy, DMT exposure and ... -
Risk of secondary progressive multiple sclerosis: A longitudinal study
Fambiatos, Adam; Jokubaitis, Vilija; Horakova, Dana; Havrdova, Eva Kubala; Trojano, Maria; Prat, Alexandre; Turkoglu, Recai (Sage Publications Ltd, 2020)Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and ... -
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Kalincik, Tomas; Horakova, Dana; Spelman, Tim; Jokubaitis, Vilija; Trojano, Maria; Lugaresi, Alessandra; Bergamaschi, Roberto (Wiley, 2015)ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly ... -
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Kalincik, Tomas; Manouchehrinia, Ali; Sobisek, Lukas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Iuliano, Gerardo (Oxford Univ Press, 2017)Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response ...
